clinical trial design
DESCRIPTION
به نام ايزد يکتا. Clinical Trial Design. The common types Advantages and limitations Usual applications. Clinical Trial (on patients) vs. Field Trial (on healthy people) Community Trial (on communities). Before. After. Intervention. In phase II clinical trials OR - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/1.jpg)
1
به نام ايزد يکتا
Clinical Trial Design
Dr. Khalili
The common types Advantages and limitations Usual applications
![Page 2: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/2.jpg)
Dr. Khalili 2
Clinical Trial (on patients)vs.
Field Trial (on healthy people)
Community Trial (on communities)
![Page 3: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/3.jpg)
Dr. Khalili 3
![Page 4: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/4.jpg)
Dr. Khalili 4
AfterBefore Intervention
In phase II clinical trials OR in serious diseases such as cancers
![Page 5: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/5.jpg)
Dr. Khalili 5
![Page 6: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/6.jpg)
Dr. Khalili 6
![Page 7: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/7.jpg)
Dr. Khalili 7
![Page 8: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/8.jpg)
Dr. Khalili 8
![Page 9: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/9.jpg)
Dr. Khalili 9
![Page 10: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/10.jpg)
Dr. Khalili 10
![Page 11: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/11.jpg)
Dr. Khalili 11
![Page 12: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/12.jpg)
Dr. Khalili 12
Notice: the standard methods for sample size calculation and data analysis considering subject as analysis unit are not appropriate here.
![Page 13: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/13.jpg)
Dr. Khalili 13
Be relax forfew minutes
![Page 14: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/14.jpg)
Dr. Khalili 14
![Page 15: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/15.jpg)
Dr. Khalili 15
• Advantages:
Allows within-patients comparisons of treatments
Removes interpatient variabilityProvides the best unbiased estimates for
the differences between treatmentsDecreases number of patients needed
![Page 16: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/16.jpg)
Dr. Khalili 16
• Limitations:• It is applicable where:
Objective measures for efficacy and safety are obtained Chronic and relatively stable disease Prophylactic drugs with relatively short half life Relatively short treatment periods Baseline and washout periods are feasible
• It increases the duration of the study• Its analysis is not straightforward:
The paired design The period and carry-over effects
• The effect of loss to follow-up
![Page 17: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/17.jpg)
Dr. Khalili 17
• Sequence (Period) Effect: The order in which the therapies are given may
elicit psychological responses. Patients may react differently to the first
therapy given in a study as a result of the enthusiasm may diminish over
time.
• Carryover Effect: If a subject is changed from therapy A to therapy B and
observed under each therapy, the observations under therapy B will be
valid only if there is no residual carryover from therapy A. There must be
enough of a washout period to be sure none of therapy A or its effect
remains.
![Page 18: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/18.jpg)
Dr. Khalili 18
![Page 19: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/19.jpg)
Dr. Khalili 19
To resolve the problom:
![Page 20: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/20.jpg)
Two applications:1. Quantifying the interaction between the
two treatments2. Opportunistic situations
![Page 21: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/21.jpg)
Dr. Khalili 21
A Full (a+1) * (b+1) Factorial Design for Combination Therapy of Two Components at a and b Dose Levels
![Page 22: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/22.jpg)
Dr. Khalili 22
Designs with ethical considerations
• Adaptive Randomization
• Zelen design
• Variations of placebo-controlled trials:
• Add-on design
• Replacement design
• Randomized Withdrawal design
• Sequential analysis
![Page 23: Clinical Trial Design](https://reader036.vdocuments.site/reader036/viewer/2022062315/5681614f550346895dd0d51a/html5/thumbnails/23.jpg)
Dr. Khalili 23
And more complex DESIGNS …